CANVAXIN FAILS TO DEMONSTRATE EFFICACY AS POST-SURGICAL ADJUVANT TREATMENT

CancerVax has reported that data from its Phase III clinical trials of Canvaxin did not demonstrate efficacy as a post-surgical adjuvant treatment for patients with advanced-stage melanoma.

A data safety monitoring board, upon the review of trial data at the third interim analysis, found that the trial would not provide significant evidence of a survival benefit for Canvaxin-treated patients versus those receiving placebo. A total of 1,160 patients were enrolled in the trial.